[Adverse reactions to diphtheria-pertussis-tetanus vaccine in the Chilean Immunization Program].
BACKGROUND
During 2005, the surveillance system of the Chilean Immunization Program detected an increased number of adverse reaction notifications associated to diphtheria, pertussis and tetanus whole-cell vaccine (DPT), coincidently with a change in the vaccine manufacturer.


OBJECTIVE
To compare the reactogenicity of two DPT formulations (vaccines 1 and 2) in 18-month-old infants and 4-year-old children.


METHODS
Severe adverse reactions to DPT were studied at the emergency room of two hospitals of Santiago in a case-control study (110 cases and 171 controls, who consulted for other causes). Simultaneously the incidence of total adverse reactions (mild and severe) for vaccine 1 and 2 was estimated in a cohort of 1,017 children vaccinated in an ambulatory health center of the same area. The formulation of DPT received by all participants was verified, as well as the temporal relation with consultation or symptoms referred by their caregivers.


RESULTS
There was a greater probability of consulting at the emergency rooms for severe adverse reactions among children who received vaccine 1 (odds ratio (OR) =7.1; p <0.001), being greater among 4-year-old children (OR =18.9; p <0.001). Coincidently, in the cohort of vaccinated children, those who received vaccine 1 had a higher risk of presenting adverse reactions (RR =2.9; p <0.001), being high fever the commonest.


CONCLUSIONS
We confirmed that vaccine 1 was associated to a higher risk of adverse reactions, especially among 4-year-old children. These results allowed the sanitary authority to adopt an informed decision. The usefulness of observational studies in vaccine adverse reactions is confirmed.
Abarca V
Katia
K
Departamentos de Pediatría, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago de Chile.
Cerda L
Jaime
J
Ferreccio R
Catterina
C
D016907:Adverse Drug Reaction Reporting Systems / Q000592:standards / Q000706:statistics & numerical data*; D016022:Case-Control Studies; D002677:Chile; D004165:Diphtheria / Q000517:prevention & control*; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects*; D006801:Humans; D017589:Immunization Programs / Q000592:standards*; D015994:Incidence; D011159:Population Surveillance; D013742:Tetanus / Q000517:prevention & control*; D014917:Whooping Cough / Q000517:prevention & control*
D015721:Diphtheria-Tetanus-Pertussis Vaccine